Why the study?
What is the appropriate method and schedule for monitoring cardiac function to prevent anthracycline-induced cardiotoxicity in patients receiving anthracycline therapy?
What is the appropriate method and schedule for monitoring cardiac function to prevent anthracycline-induced cardiotoxicity in patients receiving anthracycline therapy?
Current literature and guidelines lack sufficient evidence to definitively guide the optimal method and schedule for monitoring anthracycline-induced cardiotoxicity, though following existing guidelines remains a practical interim solution.
No takes yet. Share an insight, caveat, or question.
Insufficient evidence precludes evidence-based anthracycline monitoring protocols; prospective trials needed to define optimal strategies.
Jannazzo et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: